Abstract:Background
Prevalence estimates of COVID‐19‐related posttraumatic stress disorder (PTSD) have ranged from 1% to over 60% in the general population. Individuals with lived experience of a psychiatric disorder may be particularly vulnerable to COVID‐19‐related PTSD but this has received inadequate attention.
Methods
Participants were 1571 adults with lived experience of psychiatric disorder who took part in a longitudinal study of mental health during the COVID‐19 pandemic. PTSD was assessed by the International… Show more
“…Only genetic liabilities to COVID-19 and MDD were considered, with no regard to the confounding effects of other factors, such as posttraumatic stress disorder and insomnia, which have been shown to be closely correlated with MDD and COVID-19. [48][49][50][51] Implications In summary, our study supports that MDD may augment the susceptibility to COVID-19, primarily through the priming of neuroinflammatory cascades. Our findings emphasise the need to increase social support and improve the networks of mental health interventions for people with mood disorders during the pandemic.…”
Section: Limitationssupporting
confidence: 65%
“…Therefore, our results may not be suitable for other populations. Only genetic liabilities to COVID-19 and MDD were considered, with no regard to the confounding effects of other factors, such as post-traumatic stress disorder and insomnia, which have been shown to be closely correlated with MDD and COVID-19 48–51…”
BackgroundWe aimed to evaluate whether major depressive disorder (MDD) could aggravate the outcomes of coronavirus disease 2019 (COVID-19) or whether the genetic liability to COVID-19 could trigger MDD.AimsWe aimed to assess bidirectional causal associations between MDD and COVID-19.MethodsWe performed genetic correlation and Mendelian randomisation (MR) analyses to assess potential associations between MDD and three COVID-19 outcomes. Literature-based network analysis was conducted to construct molecular pathways connecting MDD and COVID-19.ResultsWe found that MDD has positive genetic correlations with COVID-19 outcomes (rg: 0.10–0.15). Our MR analysis indicated that genetic liability to MDD is associated with increased risks of COVID-19 infection (odds ratio (OR)=1.05, 95% confidence interval (CI): 1.00 to 1.10, p=0.039). However, genetic liability to the three COVID-19 outcomes did not confer any causal effects on MDD. Pathway analysis identified a panel of immunity-related genes that may mediate the links between MDD and COVID-19.ConclusionsOur study suggests that MDD may increase the susceptibility to COVID-19. Our findings emphasise the need to increase social support and improve mental health intervention networks for people with mood disorders during the pandemic.
“…Only genetic liabilities to COVID-19 and MDD were considered, with no regard to the confounding effects of other factors, such as posttraumatic stress disorder and insomnia, which have been shown to be closely correlated with MDD and COVID-19. [48][49][50][51] Implications In summary, our study supports that MDD may augment the susceptibility to COVID-19, primarily through the priming of neuroinflammatory cascades. Our findings emphasise the need to increase social support and improve the networks of mental health interventions for people with mood disorders during the pandemic.…”
Section: Limitationssupporting
confidence: 65%
“…Therefore, our results may not be suitable for other populations. Only genetic liabilities to COVID-19 and MDD were considered, with no regard to the confounding effects of other factors, such as post-traumatic stress disorder and insomnia, which have been shown to be closely correlated with MDD and COVID-19 48–51…”
BackgroundWe aimed to evaluate whether major depressive disorder (MDD) could aggravate the outcomes of coronavirus disease 2019 (COVID-19) or whether the genetic liability to COVID-19 could trigger MDD.AimsWe aimed to assess bidirectional causal associations between MDD and COVID-19.MethodsWe performed genetic correlation and Mendelian randomisation (MR) analyses to assess potential associations between MDD and three COVID-19 outcomes. Literature-based network analysis was conducted to construct molecular pathways connecting MDD and COVID-19.ResultsWe found that MDD has positive genetic correlations with COVID-19 outcomes (rg: 0.10–0.15). Our MR analysis indicated that genetic liability to MDD is associated with increased risks of COVID-19 infection (odds ratio (OR)=1.05, 95% confidence interval (CI): 1.00 to 1.10, p=0.039). However, genetic liability to the three COVID-19 outcomes did not confer any causal effects on MDD. Pathway analysis identified a panel of immunity-related genes that may mediate the links between MDD and COVID-19.ConclusionsOur study suggests that MDD may increase the susceptibility to COVID-19. Our findings emphasise the need to increase social support and improve mental health intervention networks for people with mood disorders during the pandemic.
“…To contextualize the study's findings, we note that most study participants were women, had advanced secondary degrees, had full-time jobs with annual incomes greater than $80,000, reported India as their country of birth, and adhered to Hinduism as their religion. Further, in light of literature indicating how the pandemic contributed to the development and/or worsening of PTSD symptoms and to traumatic experiences (Lewis et al, 2022), we note that 27% of our participants provided responses during the early months of the COVID-19 pandemic. Broadly, our findings extend recent literature calling for more empirical research on PTSD prevalence and treatment (Contractor et al, 2022) and sociocultural barriers for mental health services (Roberts et al, 2016) among the Asian Indian community.…”
“…In the total sample, 5.4% ( n = 77) of participants reported a traumatic experience that was judged to meet the ICD‐11 criteria for PTSD, and 0.84% of participants ( n = 13) met the criteria for probable COVID‐19–related PTSD. A more detailed account of the findings related to PTSD is reported elsewhere (C. Lewis, Lewis, Roberts, Evison, et al., 2022 ).…”
Although the COVID-19 pandemic has been shown to be detrimental to mental health, it may hold a parallel potential for positive change. Little is known about posttraumatic growth (PTG) as a potential outcome for individuals with lived experience of psychiatric disorders following trauma exposure, especially in the context of the COVID-19 pandemic. Participants were 1,424 adults with lived experience of a psychiatric disorder who took part in a longitudinal study of mental health during the COVID-19 pandemic conducted by the National Centre for Mental Health. PTG was measured using the Posttraumatic Growth Inventory-Short Form (PTGI-SF). Factors hypothesized to be associated with PTG were investigated using linear regression. The mean participant PTGI score was 12.64 (SD = 11.01). On average, participants reported the highest scores on items related to appreciation of life and lowest on those related to spiritual change subscale. We found the strongest evidence of associations between higher levels of PTG and higher scores on assessment items related to perceived social support, B = 2.86; perceptions of the pandemic as traumatic, B = 4.89; and higher psychological well-being, B = 0.40. Taken together, we did not observe evidence of widespread PTG related to the COVID-19 pandemic among individuals with lived experiences of psychiatric disorders.In March 2020, the World Health Organization (WHO) declared the COVID-19 outbreak to be a global pandemic (Cucinotta & Vanelli, 2020). To save lives and safeguard against health systems becoming overwhelmed, governments around the world enacted unprecedented social distancing and lockdown measures to mitigate the spread of the virus. These measures, combined with the threat This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.